Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

Pulling Back the Curtain: Gerald A. Soff, MD

Hear more from our interview with Dr. Soff, where he shares more about his career in hematology, his myeloma diagnosis, and why Sergio Giralt, MD, is...
video

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
video

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell...

Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
video

Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL

Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
video

Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas

Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
video

Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the severity of cytokine release syndrome in patients...
video

Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment

Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
video

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy Safe, Effective in Older Patients with...

Dr. Short shares results from a “proof-of-concept” study of the combination of inotuzumab ozogamicin and mini-hyper-CVD chemotherapy in older patients with newly diagnosed acute...
video

Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

The novel anti-CD20 monoclonal antibody ublituximab (when added to ibrutinib) yielded superior response rates than ibrutinib alone in patients with high-risk chronic lymphocytic leukemia....
video

Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

Dr. Mesa reviews data from the SIMPLIFY 1 trial, which compared the novel JAK1/2 inhibitor momelotinib with ruxolintinib in patients with JAK inhibitor–naïve MF,...
Advertisement

Current Issue

October 2017, Volume 3, Issue 12

This issue features a look at hospital ranking systems, the risks and benefits of opioids for pain management, and more.